BPC-157 vs KPV
How BPC-157 and KPV differ on mechanism, dosing, and the strength of the evidence behind each.
How this is graded
Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.
BPC-157
BPC-157 is a 15-amino-acid partial sequence of body protection compound found in gastric juice. It is widely used in recovery protocols for its reported effects on tendon, ligament, muscle, and gut-lining repair. Mechanistically it is associated with upregulation of growth factor receptors and promotion of angiogenesis (new blood vessel formation), which supports tissue healing. It is frequently stacked with TB-500 for synergistic recovery and is a cornerstone of the healing-focused peptide protocol. Human clinical data is limited; most evidence is preclinical.
KPV
KPV (Lysine-Proline-Valine) is a synthetic tripeptide corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), residues 11-13. It retains α-MSH's anti-inflammatory melanocortin signaling but, being only three amino acids, lacks the pigmentation-darkening and sexual-arousal effects seen with full-length analogs like Melanotan II. Research interest centers on gut inflammation, skin inflammation, and wound healing via modulation of the NF-κB pathway. It's sold only as a research compound — no clinical trial or FDA approval data exists.
Evidence compared
| BPC-157 | KPV | |
|---|---|---|
| Research grade | Cgrade | Dgrade |
| Reported dose | 250–500 mcg | 200–500 mcg |
| Frequency | 1-2x daily | 1x daily |
| Half-life | ~30 minutes | Likely minutes (unmodified tripeptide) — no formal human pharmacokinetic data exists |
| Routes | subcutaneous, oral, intramuscular | subcutaneous, oral, topical |
| Tracked outcomes | Joint & Tendon Health, Gut Health, Cognitive Function | — |
| Contraindications | active malignancy, pregnancy | pregnancy, active malignancy, known CNS disorders without physician oversight |
Which has more behind it
BPC-157 carries the stronger evidence grade (C) against KPV at D, which means more of what is claimed for BPC-157 has been tested in humans. Both entries link through to the full reference, where the trial list and citations for each claim are set out in full.
Full BPC-157 reference · Full KPV reference
At a glance
| Compound | Grade | Reported dose | Half-life |
|---|---|---|---|
| BPC-157 | Cgrade | 250–500 mcg · 1-2x daily | ~30 minutes |
| KPV | Dgrade | 200–500 mcg · 1x daily | Likely minutes (unmodified tripeptide) — no formal human pharmacokinetic data exists |
Frequently asked questions
BPC-157 or KPV, which has better evidence?
BPC-157 carries the stronger evidence grade (C) against KPV at D, which means more of what is claimed for BPC-157 has been tested in humans.
Can BPC-157 and KPV be used together?
BPC-157 and KPV are commonly paired in reported protocols. Combining compounds does not combine their evidence, each still carries its own grade.
What doses are reported for BPC-157?
Published protocols report 250–500 mcg, 1-2x daily. This is what the literature describes, not a recommendation.
References
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Sikiric P, et al. · 2011
- Brain-gut axis and pentadecapeptide BPC 157 · Sikiric P, et al. · 2016
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. · Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM · 2025
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. · Lee E, Padgett B · 2021
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM · 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. · Lee E, Walker C, Ayadi B · 2024
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. · Chang CH, Tsai WC, Hsu YH, Pang JH · 2014
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. · Lee E, Burgess K · 2025
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats · Xue XC, Wu YJ, Gao MT, Li WG, Zhao N, Wang ZL, Bao CJ, Yan Z, Zhang YQ · 2004
- ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial.
- Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats. · Mirković I, Kralj T, Lozić M et al. · 2020
- The pharmacological properties of the novel peptide BPC 157 (PL-10) · Sikiric P · 1999
- Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. · Amic F, Drmic D, Bilic Z et al. · 2018
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation · Dalmasso G, et al. · 2008